评价泊沙康唑与伏立康唑治疗侵袭性曲霉病的有效性与安全性的3期随机研究
[Translation] Phase 3 randomized study evaluating the efficacy and safety of posaconazole and voriconazole in the treatment of invasive aspergillosis
一项评价泊沙康唑与伏立康唑治疗成人和青少年侵袭性曲霉病的有效性与安全性的3期随机研究(3期;方案编号 MK-5592-069)
[Translation] A Phase 3 randomized study evaluating the efficacy and safety of posaconazole versus voriconazole in adults and adolescents with invasive aspergillosis (Phase 3; protocol number MK-5592-069)
一项评价泊沙康唑(MK5592,POS)经静脉(IV)输注液和口服片剂给药在健康中国受试者中药代动力学特征的研究
[Translation] A study to evaluate the pharmacokinetics of posaconazole (MK5592, POS) administered by intravenous (IV) infusion and oral tablet in healthy Chinese subjects
1在健康中国受试者中评价POS静脉(IV)输注液及片剂在空腹状态下单次给药的药代动力学特征。 2将在健康中国受试者中评价食物对POS 吸收的影响
[Translation] 1 To evaluate the pharmacokinetics of single-dose POS intravenous (IV) infusion solutions and tablets in healthy Chinese subjects in the fasted state. 2 The effect of food on POS absorption will be evaluated in healthy Chinese subjects
100 Clinical Results associated with Schering-Plough Brinny Co.
0 Patents (Medical) associated with Schering-Plough Brinny Co.
100 Deals associated with Schering-Plough Brinny Co.
100 Translational Medicine associated with Schering-Plough Brinny Co.